Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolastatin-10 in Advanced Renal Cell Carcinoma
NCT00003914Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 1999
- Primary completion
- Aug 2002
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dolastatin 10 in renal cell carcinoma (RCC), sponsored by Mayo Clinic. Primary endpoint: Response Rate. Started Aug 1999; status: completed.
02
Drugs
dolastatin 10
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00003914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003914.